WA
DNLI icon

Wasatch Advisors’s Denali Therapeutics DNLI Stock Holding History

Wasatch Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-238,881
Closed -$6.96M – 238
2024
Q3 		$6.96M Sell
238,881
-163,528
-41% -$4.05M 0.03% 183
2024
Q2 		$9.34M Sell
402,409
-261
-0.1% -$5.01K 0.05% 156
2024
Q1 		$8.26M Buy
402,670
+90,369
+29% +$1.7M 0.04% 174
2023
Q4 		$6.7M Sell
312,301
-9,166
-3% -$182K 0.04% 181
2023
Q3 		$6.63M Sell
321,467
-510,830
-61% -$13M 0.04% 175
2023
Q2 		$24.6M Buy
832,297
+274,130
+49% +$7.71M 0.15% 113
2023
Q1 		$12.9M Buy
558,167
+107,217
+24% +$2.95M 0.08% 150
2022
Q4 		$12.5M Buy
450,950
+91,477
+25% +$2.72M 0.08% 157
2022
Q3 		$11M Buy
359,473
+17,799
+5% +$579K 0.08% 166
2022
Q2 		$10.1M Buy
341,674
+104,251
+44% +$2.73M 0.06% 170
2022
Q1 		$7.64M Buy
237,423
+63,181
+36% +$2.17M 0.04% 201
2021
Q4 		$7.77M Sell
174,242
-286
-0.2% -$13.5K 0.03% 215
2021
Q3 		$8.8M Sell
174,528
-362,718
-68% -$20.4M 0.04% 216
2021
Q2 		$42.1M Buy
537,246
+58,804
+12% +$3.64M 0.17% 118
2021
Q1 		$27.3M Sell
478,442
-2,842
-0.6% -$190K 0.12% 144
2020
Q4 		$40.3M Sell
481,284
-853,901
-64% -$51.6M 0.2% 104
2020
Q3 		$47.8M Buy
1,335,185
+131,775
+11% +$3.97M 0.3% 94
2020
Q2 		$29.1M Buy
1,203,410
+63,153
+6% +$1.48M 0.21% 110
2020
Q1 		$20M Buy
1,140,257
+83,411
+8% +$1.74M 0.21% 96
2019
Q4 		$18.4M Buy
1,056,846
+79,185
+8% +$1.32M 0.15% 114
2019
Q3 		$15M Sell
977,661
-18,486
-2% -$353K 0.14% 116
2019
Q2 		$20.7M Buy
996,147
+175,243
+21% +$3.93M 0.2% 101
2019
Q1 		$19.1M Buy
820,904
+775,358
+1,702% +$16.2M 0.21% 88
2018
Q4 		$941K Sell
45,546
-13,723
-23% -$249K 0.01% 222
2018
Q3 		$1.29M Buy
59,269
+28,138
+90% +$465K 0.01% 226
2018
Q2 		$475K Hold
31,131
– – 0.01% 270
2018
Q1 		$613K Hold
31,131
– – 0.01% 268
2017
Q4 		$487K Buy
+31,131
New +$559K 0.01% 280

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wasatch Advisors's DNLI Position: Q4 2024 in Review

Wasatch Advisors sold out of Denali Therapeutics (DNLI) in Q4 2024, closing a stake of 238,881 shares — an estimated $6.96M sold.

Wasatch Advisors first reported a position in DNLI in Q4 2017 and held it in 28 quarters. The position peaked at $47.8M in Q3 2020. 223 funds tracked by Wall St. Rank hold DNLI as of Q4 2024.

  • Wasatch Advisors reported no remaining Denali Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Wasatch Advisors sold 238,881 Denali Therapeutics shares in Q4 2024, an estimated $6.96M.
  • Wasatch Advisors first reported a position in Denali Therapeutics in Q4 2017 and held it in 28 quarters.
  • Wasatch Advisors's Denali Therapeutics position peaked at $47.8M in Q3 2020.
  • 223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2024.

Based on Wasatch Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.